NDC product
Naproxen Sodium and Diphenhydramine HCL
NDC 11673-819 · TARGET CORPORATION
Key facts
| Product NDC | 11673-819 |
|---|---|
| Proprietary name | Naproxen Sodium and Diphenhydramine HCL |
| Nonproprietary name | Naproxen Sodium and Diphenhydramine HCL |
| Substances | DIPHENHYDRAMINE HYDROCHLORIDE, NAPROXEN SODIUM |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | TARGET CORPORATION |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA213663 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Nonsteroidal Anti-inflammatory Drug [EPC] |
| Marketing start | Mar 1, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: